Physician profile
April Rosalez
NPI 1255694352
$361.80
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.70 · 2020: $74.91 · 2021: $178 · 2022: $20.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $122.93 | 2019-2021 | |
| Amgen INC. | $48.59 | 2020-2021 | |
| Abbvie INC. | $38.25 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $37.69 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.89 | 2019 | |
| Grifols USA, LLC | $20.16 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.00 | 2019 | |
| Eisai INC. | $15.73 | 2021 | |
| Merck Sharp & Dohme LLC | $15.66 | 2021 | |
| Novo Nordisk INC | $11.90 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Rosalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.